[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Urinary Incontinence (Genitourinary Disorders) - Drugs in Development, 2021

March 2021 | 72 pages | ID: UB35755D3C3FEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Urinary Incontinence (Genitourinary Disorders) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Drugs in Development, 2021, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 9 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Urinary Incontinence - Overview
Urinary Incontinence - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Urinary Incontinence - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Urinary Incontinence - Companies Involved in Therapeutics Development
Cook MyoSite Inc
Crystec Ltd
Exopharm Ltd
FemmePharma Global Healthcare Inc
Innovacell Biotechnologie AG
Ixaltis
Johnson & Johnson
MUVON Therapeutics AG
Ningbo Xijian Pharmaceutical Technology Co Ltd
Outpost Medicine Ltd
Pfizer Inc
Profem GmbH
Revance Therapeutics Inc
RION Health Inc
Saniona AB
Sinsin Pharmaceutical Co Ltd
Taiho Pharmaceutical Co Ltd
Versameb AG
Urinary Incontinence - Drug Profiles
Biologic for Stress Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Stress Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Urinary Stress Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cevaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICES-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iltamiocel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
litoxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Stress Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prof-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolterodine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trospium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Urinary Incontinence - Dormant Projects
Urinary Incontinence - Discontinued Products
Urinary Incontinence - Product Development Milestones
Featured News & Press Releases
Dec 17, 2020: FDA grants RMAT designation for Cook MyoSite’s investigational autologous Muscle Derived Cells for Urinary Sphincter Repair
Jan 11, 2018: Sleep quality improves with help of incontinence drug
Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency
Aug 30, 2011: Innovacell passes a further milestone
Feb 22, 2011: Innovacell makes further progress on product development
Jun 15, 2010: Innovacell Enrolls First Patient In Phase IIb Study Of Urocell For Treatment Of Urinary Incontinence
Oct 31, 2008: Fesoterodine Approved in the U.S
Sep 15, 2003: FemmePharma Receives U.S. Ind Approval for its New Therapeutic Option for Female Urinary Incontinence
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Urinary Incontinence, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Urinary Incontinence - Pipeline by Cook MyoSite Inc, 2021
Urinary Incontinence - Pipeline by Crystec Ltd, 2021
Urinary Incontinence - Pipeline by Exopharm Ltd, 2021
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, 2021
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, 2021
Urinary Incontinence - Pipeline by Ixaltis, 2021
Urinary Incontinence - Pipeline by Johnson & Johnson, 2021
Urinary Incontinence - Pipeline by MUVON Therapeutics AG, 2021
Urinary Incontinence - Pipeline by Ningbo Xijian Pharmaceutical Technology Co Ltd, 2021
Urinary Incontinence - Pipeline by Outpost Medicine Ltd, 2021
Urinary Incontinence - Pipeline by Pfizer Inc, 2021
Urinary Incontinence - Pipeline by Profem GmbH, 2021
Urinary Incontinence - Pipeline by Revance Therapeutics Inc, 2021
Urinary Incontinence - Pipeline by RION Health Inc, 2021
Urinary Incontinence - Pipeline by Saniona AB, 2021
Urinary Incontinence - Pipeline by Sinsin Pharmaceutical Co Ltd, 2021
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, 2021
Urinary Incontinence - Pipeline by Versameb AG, 2021
Urinary Incontinence - Dormant Projects, 2021
Urinary Incontinence - Dormant Projects, 2021 (Contd..1)
Urinary Incontinence - Dormant Projects, 2021 (Contd..2)
Urinary Incontinence - Discontinued Products, 2021

LIST OF FIGURES

Number of Products under Development for Urinary Incontinence, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


More Publications